tetano
Editor, Senior Moderator
EBioMedicine. 2018 Feb 15. pii: S2352-3964(18)30065-3. doi: 10.1016/j.ebiom.2018.02.011. [Epub ahead of print]
[h=1]Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.[/h] Coughlan L[SUP]1[/SUP], Sridhar S[SUP]2[/SUP], Payne R[SUP]3[/SUP], Edmans M[SUP]3[/SUP], Milicic A[SUP]3[/SUP], Venkatraman N[SUP]3[/SUP], Lugonja B[SUP]3[/SUP], Clifton L[SUP]4[/SUP], Qi C[SUP]4[/SUP], Folegatti PM[SUP]3[/SUP], Lawrie AM[SUP]3[/SUP], Roberts R[SUP]3[/SUP], de Graaf H[SUP]5[/SUP], Sukhtankar P[SUP]5[/SUP], Faust SN[SUP]5[/SUP], Lewis DJM[SUP]6[/SUP], Lambe T[SUP]3[/SUP], Hill A[SUP]3[/SUP], Gilbert SC[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] T-cell responses against highly conserved influenza antigens have been previously associated with protection. However, these immune responses are poorly maintained following recovery from influenza infection and are not boosted by inactivated influenza vaccines. We have previously demonstrated the safety and immunogenicity of two viral vectored vaccines, modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAdOx1 expressing conserved influenza virus antigens, nucleoprotein (NP) and matrix protein-1 (M1). We now report on the safety and long-term immunogenicity of multiple combination regimes of these vaccines in young and older adults.
[h=4]METHODS:[/h] We conducted a Phase I open-label, randomized, multi-center study in 49 subjects aged 18-46years and 24 subjects aged 50years or over. Following vaccination, adverse events were recorded and the kinetics of the T cell response determined at multiple time points for up to 18months.
[h=4]FINDINGS:[/h] Both vaccines were well tolerated. A two dose heterologous vaccination regimen significantly increased the magnitude of pre-existing T-cell responses to NP and M1 after both doses in young and older adults. The fold-increase and peak immune responses after a single MVA-NP+M1 vaccination was significantly higher compared to ChAdOx1 NP+M1. In a mixed regression model, T-cell responses over 18months were significantly higher following the two dose vaccination regimen of MVA/ChAdOx1 NP+M1.
[h=4]INTERPRETATION:[/h] A two dose heterologous vaccination regimen of MVA/ChAdOx1 NP+M1 was safe and immunogenic in young and older adults, offering a promising vaccination strategy for inducing long-term broadly cross-reactive protection against influenza A.
[h=4]FUNDING SOURCE:[/h] Medical Research Council UK, NIHR BMRC Oxford.
Copyright ? 2018 The Authors. Published by Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Adults; Influenza; Influenza vaccines; Older adults; T-cell responses; Viral vectors
PMID: 29519670 DOI: 10.1016/j.ebiom.2018.02.011
Free full text
[h=1]Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.[/h] Coughlan L[SUP]1[/SUP], Sridhar S[SUP]2[/SUP], Payne R[SUP]3[/SUP], Edmans M[SUP]3[/SUP], Milicic A[SUP]3[/SUP], Venkatraman N[SUP]3[/SUP], Lugonja B[SUP]3[/SUP], Clifton L[SUP]4[/SUP], Qi C[SUP]4[/SUP], Folegatti PM[SUP]3[/SUP], Lawrie AM[SUP]3[/SUP], Roberts R[SUP]3[/SUP], de Graaf H[SUP]5[/SUP], Sukhtankar P[SUP]5[/SUP], Faust SN[SUP]5[/SUP], Lewis DJM[SUP]6[/SUP], Lambe T[SUP]3[/SUP], Hill A[SUP]3[/SUP], Gilbert SC[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] T-cell responses against highly conserved influenza antigens have been previously associated with protection. However, these immune responses are poorly maintained following recovery from influenza infection and are not boosted by inactivated influenza vaccines. We have previously demonstrated the safety and immunogenicity of two viral vectored vaccines, modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAdOx1 expressing conserved influenza virus antigens, nucleoprotein (NP) and matrix protein-1 (M1). We now report on the safety and long-term immunogenicity of multiple combination regimes of these vaccines in young and older adults.
[h=4]METHODS:[/h] We conducted a Phase I open-label, randomized, multi-center study in 49 subjects aged 18-46years and 24 subjects aged 50years or over. Following vaccination, adverse events were recorded and the kinetics of the T cell response determined at multiple time points for up to 18months.
[h=4]FINDINGS:[/h] Both vaccines were well tolerated. A two dose heterologous vaccination regimen significantly increased the magnitude of pre-existing T-cell responses to NP and M1 after both doses in young and older adults. The fold-increase and peak immune responses after a single MVA-NP+M1 vaccination was significantly higher compared to ChAdOx1 NP+M1. In a mixed regression model, T-cell responses over 18months were significantly higher following the two dose vaccination regimen of MVA/ChAdOx1 NP+M1.
[h=4]INTERPRETATION:[/h] A two dose heterologous vaccination regimen of MVA/ChAdOx1 NP+M1 was safe and immunogenic in young and older adults, offering a promising vaccination strategy for inducing long-term broadly cross-reactive protection against influenza A.
[h=4]FUNDING SOURCE:[/h] Medical Research Council UK, NIHR BMRC Oxford.
Copyright ? 2018 The Authors. Published by Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Adults; Influenza; Influenza vaccines; Older adults; T-cell responses; Viral vectors
PMID: 29519670 DOI: 10.1016/j.ebiom.2018.02.011
Free full text